Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 11.2% – Here’s What Happened

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) fell 11.2% during trading on Monday . The stock traded as low as $0.81 and last traded at $0.86. 245,588 shares changed hands during trading, an increase of 36% from the average session volume of 180,373 shares. The stock had previously closed at $0.97.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price target on shares of Citius Pharmaceuticals in a report on Tuesday, February 18th.

Citius Pharmaceuticals Trading Down 11.2 %

The business’s 50-day moving average is $1.49 and its 200-day moving average is $3.96.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its earnings results on Friday, February 14th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($0.05). Equities analysts anticipate that Citius Pharmaceuticals, Inc. will post -4.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its holdings in shares of Citius Pharmaceuticals by 103.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,212 shares of the company’s stock valued at $33,000 after acquiring an additional 4,168 shares during the last quarter. Fisher Asset Management LLC purchased a new position in Citius Pharmaceuticals in the 4th quarter valued at $51,000. IFP Advisors Inc boosted its stake in Citius Pharmaceuticals by 21.2% during the 4th quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock worth $162,000 after purchasing an additional 7,083 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Citius Pharmaceuticals in the third quarter valued at about $47,000. Finally, Virtu Financial LLC purchased a new position in shares of Citius Pharmaceuticals in the third quarter worth about $50,000. 16.88% of the stock is owned by hedge funds and other institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.